Nrf2-Dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer
S. C. Hwang, Y. J. Jung, W. Y. Jung, K. S. Lee, J. H. Park, Y. S. Kim, H. L. Lee, K. J. Park (Suwon, Republic Of Korea)
Source: Annual Congress 2010 - Pathology of lung cancer
Session: Pathology of lung cancer
Session type: Thematic Poster Session
Number: 3269
Disease area: Thoracic oncology
Abstract Nrf2-Dependent Overexpression of Sulfiredoxin and Peroxiredoxin III in Human Lung Cancer. Oxidative stress results in protein oxidation and is implicated in the pathogenesis of human carcinogenesis. Sulfiredoxin (Srx) is a protein responsible for the enzymatic reversal of inactivated peroxiredoxins (Prxs). Nuclear factor E2-related factor 2 (Nrf2) is a master transcription factor that upregulates the expression of Srx and Prx during oxidative stress. We aimed to elucidate the biological function of Srx and to explore the potential role of Nrf2/ARE-regulated protein in human carcinogenesis. To study the contribution of Srx and Prx III to human lung cancer, we compared the protein levels of Nrf2, Prxs, thioredoxin, and Srx in 40 surgically resected human lung cancer tissues with paired normal tissues, using immunoblot and immunohistochemical analyses. Densitometry was used to measure the amount of expression. Prx I and Prx III proteins were markedly overexpressed in lung cancer tissues. A significant increase in the oxidized form of a cysteine sulfhydryl at the catalytic site of Prxs was found in the lung cancer tissues, compared with paired normal lung tissues. Densitometric analyses revealed significant Srx overexpression in 60% (12/20) squamous cell carcinoma tissues, but in only 20% (4/20) adenocarcinoma tissues. Furthermore, Nrf2 was present in the nuclear compartment in the cancer cells. In conclusion, Srx and Prx III proteins were markedly overexpressed in squamous cell carcinoma, suggesting that these proteins may play a protective role against oxidative injury and compensate for the high rate of mitochondrial metabolism in human lung cancer.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. C. Hwang, Y. J. Jung, W. Y. Jung, K. S. Lee, J. H. Park, Y. S. Kim, H. L. Lee, K. J. Park (Suwon, Republic Of Korea). Nrf2-Dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Eur Respir J 2010; 36: Suppl. 54, 3269
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Expression of peroxiredoxin I, III and thioredoxin in human lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 102s Year: 2005
Activation of NRF2 is responsible for the overexpression of peroxiredoxin and sulphiredoxin in human lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Decreased mRNA and protein expression of peroxiredoxin (PRDX6) in the COPD lung Source: Eur Respir J 2004; 24: Suppl. 48, 320s Year: 2004
Adenovirus-mediated AP-2α down-regulates MnSOD expression in lung cancer A549 cells and its molecular mechanism Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Inhibition of heme oxygenase-1 enhances chemosensitivity of cisplatin in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006
Expression of p53, Bcl-2 and Bax in non-small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 512s Year: 2007
Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis Source: Eur Respir J 2002; 20: 703-709 Year: 2002
Diminished expression of HOXA5 in lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003
PP138 – Regulation of PA200 in lung cancer Source: ERS Lung Science Conference 2021 Year: 2021
Regulation of PA200 in lung cancer Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Transcriptional regulation of the human osteopontin promoter in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Inhibitory effects of mitochondrial TRAP1 on gefitinib-resistancein non-small lung cancer cells Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018
Mutant P53 expression in squamous cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
The role of peroxiredoxins in the radiation-induced damage of lung cancer cells Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007
ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumour metastasis Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016
Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006
Distinct forms of BARD1 expressed in lung fibrosis and lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 325s Year: 2006
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017
Fusion transcripts in lung cancer Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017